menu
    • menu
    [{"orgOrder":0,"company":"Epsilogen","sponsor":"TigaTx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"EPS 401","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Epsilogen","highestDevelopmentStatusID":"5","companyTruncated":"Epsilogen \/ Epsilogen"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MOv18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Epsilogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Undisclosed"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Epsilogen \/ Novartis Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Epsilogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Undisclosed"},{"orgOrder":0,"company":"Epsilogen","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Epsilogen \/ British Patient Capital","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ British Patient Capital"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Epsilogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Undisclosed"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Undisclosed"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Kings College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Epsilogen"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Epsilogen \/ Innovate Biopharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Epsilogen

    Menu

    Epsilogen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPS 401

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : TigaTx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UK's Epsilogen acquires fellow immunoglobin biotech TigaTx

                            Details : The acquisition bolsters Epsilogen’s pipeline by adding EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody. It is being evaluated for treating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 07, 2025

                            Lead Product(s) : EPS 401

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : TigaTx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epsilogen Announces Initiation of Phase Ib Trial of MOv18 IgE

                            Details : MOv18 IgE, is the first therapeutic IV infused IgE antibody which is being investigated in patients with platinum-resistant ovarian cancer (PROC).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : British Patient Capital

                            Deal Size : $47.9 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Epsilogen Completes £12.5 Million Series B Financing Expansion

                            Details : The financing aims to fund the clinical development of company-lead product MOv18 IgE is the first therapeutic IgE antibody targets FRα. It is being evaluated for the treatment of ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : British Patient Capital

                            Deal Size : $47.9 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOv18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

                            Details : MOv18 IgE is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : MOv18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epsilogen Announces CTA Approval for Phase Ib Trial of MOv18 IgE in Ovarian Cancer

                            Details : MOv18 IgE, is the first therapeutic IV infused IgE antibody which is being investigated in patients with platinum-resistant ovarian cancer (PROC).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 08, 2024

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Novartis Venture Fund

                            Deal Size : $41.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing

                            Details : The proceeds from the financing will enable Epsilogen to establish clinical proof of concept for lead drug candidate MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer, an aggressive cancer with poor treatment alternatives.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 02, 2022

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Novartis Venture Fund

                            Deal Size : $41.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPS 201

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $1.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Epsilogen Announces Further Uk Government Funding for Further Development of A Novel Ig E Antibody Cancer Immu...

                            Details : Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 21, 2020

                            Lead Product(s) : EPS 201

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $1.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR

                            Details : MOv18 IgE, at the doses administered, was found to be well tolerated in almost all patients, with urticaria1 being the most frequently observed adverse event.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 27, 2020

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Epsilogen

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Kings College London

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Epsilogen Licences Experimental Ige Antibody from KCL

                            Details : The antibody developed at KCL in collaboration with Cancer Research UK is the first therapeutic IgE antibody to enter clinical trials.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 21, 2020

                            Lead Product(s) : Mov18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Kings College London

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth